Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors

Details for Australian Patent Application No. 2004236240 (hide)

Owner Bristol-Myers Squibb Company

Inventors Leftheris, Katerina; Zhao, Rulin; Dyckman, Alaric; Chen, Bang-Chi; Liu, Chunjian; Das, Jagabandhu; Wrobleski, Stephen T.

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2004236240

PCT Pub. Number WO2004/099156

Priority 60/467,029 01.05.03 US

Filing date 3 May 2004

Wipo publication date 18 November 2004

Acceptance publication date 17 June 2010

International Classifications

C07D 231/18 (2006.01) Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings

A61K 31/415 (2006.01) - 1,2-Diazoles

A61K 31/4155 (2006.01) - not condensed and containing further heterocyclic rings

A61K 31/535 (2006.01) - having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines

C07D 231/04 (2006.01) Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings

C07D 231/14 (2006.01) Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings

C07D 401/04 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 403/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 405/12 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

C07D 413/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

C07D 413/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

Event Publications

24 November 2005 PCT application entered the National Phase

  PCT publication WO2004/099156 Priority application(s): WO2004/099156

17 June 2010 Application Accepted

  Published as AU-B-2004236240

15 July 2010 Application for Amendment

  The nature of the amendment is as shown in the statement(s) filed 24 Jun 2010. Address for service in Australia - Phillips Ormonde Fitzpatrick 367 Collins Street Melbourne VIC 3000

23 September 2010 Application for Amendment

  The nature of the amendment is: Amend the invention title to read Aryl-substituted pyrazole compounds useful as kinase inhibitors. Address for service in Australia - Phillips Ormonde Fitzpatrick 367 Collins Street Melbourne VIC 3000 2005

4 November 2010 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 24 Jun 2010

20 January 2011 Amendment Made

  The nature of the amendment is: Amend invention title to read Aryl-substituted pyrazole compounds useful as kinase inhibitors

20 January 2011 Standard Patent Sealed

1 December 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004236242-Steerable /retractable cargo power drive unit

2004236239-Substituted heteroaryls as inhibitors of protein tyrosine phosphatases